

## Early independence with Cerebrolysin

Effective pharmacological treatment for  
**STROKE** patients

Neuroprotective treatment with Cerebrolysin in patients with acute stroke: a randomized controlled trial  
Ladurner et al., J Neural Transm (2005) 112:415-428

Study results triggered inclusion in  
**American Heart Association guidelines!**

**Cerebrolysin<sup>®</sup>**  
Reconnecting Neurons.  
Empowering for Life.


# Cerebrolysin supports patients to live an independent life

## Very early improvements of Activities of daily living and cognitive functions

- Less dependence on caregivers early-on
- Improved cognitive functions facilitate rehabilitation process
- Increased quality of life

### Barthel Index


p < 0.01; right-sided subgroup  
Overall significant



- **Significant superiority** in Barthel Index
- Very early improvements of **Activities of daily living**
- Barthel Index defines the point of access to rehabilitation → Earlier start possible

### MMSE<sup>1</sup>

p < 0.01; right-sided subgroup  
Overall significant



- **Significant superiority** in the MMSE<sup>1</sup>
- Very early treatment effects in cognitive functions
- Facilitates ability to follow rehabilitation instructions

## Study results triggered inclusion in American Heart Association guidelines!

<b>Titel</b>	Neuroprotective treatment with Cerebrolysin in patients with acute stroke: a randomized controlled trial
<b>Patients</b>	78 Cerebrolysin group + 68 placebo group = 146 patients in total
<b>Treatment</b>	50 ml/day for 21 days

<sup>1</sup>MMSE = Mini-Mental State Examination

ABBREVIATED PRESCRIBING INFORMATION. Name of the medicinal product: Cerebrolysin - Solution for injection. Qualitative and quantitative composition: One ml contains 215.2 mg of Cerebrolysin concentrate in aqueous solution. List of excipients: Sodium hydroxide and water for injection. Therapeutic indications: For treatment of cerebrovascular disorders. Especially in the following indications: Senile dementia of Alzheimer's type. Vascular dementia. Stroke. Craniocerebral trauma (commotio and contusio). Contraindications: Hypersensitivity to one of the components of the drug, epilepsy, severe renal impairment. Marketing Authorisation Holder: EVER Neuro Pharma GmbH, A-4866 Unterach. Only available on prescription and in pharmacies. More information about pharmaceutical form, posology and method of administration, special warnings and precautions for use, interaction with other medicinal products and other forms of interaction, fertility, pregnancy and lactation, effects on ability to drive and use machines, undesirable effects, overdose, pharmacodynamics properties, pharmacokinetic properties, preclinical safety data, incompatibilities, shelf life, special precautions for storage, nature and contents of the container and special precautions for disposal is available in the summary of product characteristics.